# Extensions - Onconova Implementation Guide v0.2.0

* [**Table of Contents**](toc.md)
* **Extensions**

## Extensions

Extensions The following extensions have been defined for this implementation guide:

* [CTCAE Grade](StructureDefinition-onconova-ext-adverse-event-ctc-grade.md) 
The grade of the adverse event as defined by the Common Terminology Criteria for Adverse Events (CTCAE). 

* [Adverse Event Mitigation](StructureDefinition-onconova-ext-adverse-event-mitigation.md) 
Details about an action taken to mitigate or manage the adverse event. 

* [Cancer Patient Age at Diagnosis](StructureDefinition-onconova-ext-cancer-patient-age-at-diagnosis.md) 
The approximate age of the patient at the time of diagnosis of the disease. 

* [Cancer Patient Age](StructureDefinition-onconova-ext-cancer-patient-age.md) 
The approximate age of the patient. 

* [Cancer Patient Cause of Death](StructureDefinition-onconova-ext-cancer-patient-cause-of-death.md) 
The cause of death for the patient. 

* [Cancer Patient Consent status](StructureDefinition-onconova-ext-cancer-patient-consent-status.md) 
The status of whether the patient has given or revoked consent for research use. 

* [Cancer Patient Data Completion Rate](StructureDefinition-onconova-ext-cancer-patient-data-completion-rate.md) 
The percentage of data elements categories that have been completed for a patient. 

* [Cancer Patient Data Contributors](StructureDefinition-onconova-ext-cancer-patient-data-contributors.md) 
The individuals or organizations that contributed to the patient's case data collection. 

* [Cancer Patient End of Records](StructureDefinition-onconova-ext-cancer-patient-end-of-records.md) 
Indicates the last known record date of a patient. 

* [Cancer Patient Overall Survival](StructureDefinition-onconova-ext-cancer-patient-overall-survival.md) 
The duration of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive. In a clinical trial, measuring the overall survival is one way to see how well a new treatment works. 

* [Cancer Patient Vital status](StructureDefinition-onconova-ext-cancer-patient-vital-status.md) 
The status of whether the patient is alive or deceased or unknown. 

* [Family Member History Cancer Morphology](StructureDefinition-onconova-ext-family-history-member-cancer-morphology.md) 
The morphology of a historical cancer associated to a family member of a patient, represented by an ICD-O-3 code. 

* [Family Member History Cancer Topography](StructureDefinition-onconova-ext-family-history-member-cancer-topography.md) 
The topography of a historical cancer associated to a family member of a patient, represented by an ICD-O-3 code. 

* [Genomic Variant Assessment Date](StructureDefinition-onconova-ext-genomic-variant-assessment-date.md) 
Date at which the genomic variant was assessed and/or reported. 

* [Histological Differentiation](StructureDefinition-onconova-ext-histological-differentiation.md) 
The histological differentiation of the tumor. 

* [Medication Administration Adjunctive Role](StructureDefinition-onconova-ext-medication-administration-adjunctive-role.md) 
Indicates the role of this medication administration in the context of the overall treatment plan. 

* [Medication Administration Combined With](StructureDefinition-onconova-ext-medication-administration-combined-with.md) 
Indicates which medication administrations were given in combination with the current medication administration. 

* [Medication Administration Cycles](StructureDefinition-onconova-ext-medication-administration-cycles.md) 
Indicates the total number of cycles for this medication administration. 

* [Medication Administration Is Primary Therapy](StructureDefinition-onconova-ext-medication-administration-is-primary-therapy.md) 
Indicates whether this medication administration is the primary therapy within a therapy line. 

* [Molecular Tumor Board CUP Characterization](StructureDefinition-onconova-ext-molecular-tumor-board-cup-characterization.md) 
A characterization of the tumor board review focused on cancer of unknown primary (CUP) origin. 

* [Molecular Tumor Board Molecular Comparison](StructureDefinition-onconova-ext-molecular-tumor-board-molecular-comparison.md) 
A comparison of molecular findings discussed during the molecular tumor board review. 

* [Molecular Tumor Board Therapeutic Recommendation](StructureDefinition-onconova-ext-molecular-tumor-board-therapeutic-recommendation.md) 
A therapeutic recommendation or follow-up action resulting from a molecular tumor board review. 

* [Primary Cancer Recurrence Of](StructureDefinition-onconova-ext-primary-cancer-recurrence-of.md) 
Indicates that the condition is a recurrence of a previous condition, and provides a reference to that previous condition. 

* [Primary Cancer Recurrence Type](StructureDefinition-onconova-ext-primary-cancer-recurrence-type.md) 
Indicates the type of recurrence for the condition (local or regional). 

* [Risk Assessment Score](StructureDefinition-onconova-ext-risk-assessment-score.md) 
The numerical score of the risk assessment. 

* [Therapy Line Intent](StructureDefinition-onconova-ext-therapy-line-intent.md) 
The intent of the therapy line, such as curative or palliative. 

* [Therapy Line Number](StructureDefinition-onconova-ext-therapy-line-number.md) 
The number representing the sequence of the therapy line in the overall treatment regimen. 

* [Therapy Line Period](StructureDefinition-onconova-ext-therapy-line-period.md) 
The period during which the therapy line was performed. 

* [Therapy Line Progression Date](StructureDefinition-onconova-ext-therapy-line-progression-date.md) 
The date when disease progression was observed during or after the therapy line. 

* [Therapy Line Progression-Free Survival](StructureDefinition-onconova-ext-therapy-line-progression-free-survival.md) 
The progression-free survival duration for the therapy line. 

* [Therapy Line Reference](StructureDefinition-onconova-ext-therapy-line-reference.md) 
A reference to the therapy line associated with this treatment. 

* [Treatment Response RECIST Is Interpreted](StructureDefinition-onconova-ext-treatment-response-recist-is-interpreted.md) 
Indicates that whether the RECIST was interpreted from a radiology report rather than extracted. 

* [Tumor Board Specialization](StructureDefinition-onconova-ext-tumor-board-specialization.md) 
The specialization or focus area of the tumor board conducting the review, such as hematologic malignancies or solid tumors. 

* [Tumor Marker Analyte](StructureDefinition-onconova-ext-tumor-marker-analyte.md) 
The specific analyte or substance being measured as a tumor marker, such as PSA, CA-125, or CEA. 

* [Tumor Mutational Burden Status](StructureDefinition-onconova-ext-tumor-mutational-burden-status.md) 
The categorical classification of the TMB status interpreted from its value. 

